Aeglea BioTherapeutics Inc
(NASDAQ:AGLE)
$11.68
0.22[1.92%]
Last update: 7:13PM (Delayed 15-Minutes)
Get Real Time Here
$11.68
0[0.00%]
Open11.330Close12.250
Vol / Avg.10.170K / 65.135KMkt Cap47.277M
Day Range11.070 - 12.42052 Wk Range2.660 - 39.000

Aeglea BioTherapeutics Stock (NASDAQ:AGLE), Short Interest Report

Short interest for Aeglea BioTherapeutics gives investors a sense of the degree to which investors are betting on the decline of Aeglea BioTherapeutics's stock. Short interest data is updated every two weeks.

Short Interest

121.2K

Short Interest %

3.03%

Days to Cover

1.89
Data brought to you by Benzinga APIs

Looking for the most shorted stocks?

Aeglea BioTherapeutics Stock (NASDAQ:AGLE), Short Interest Report

Short interest for Aeglea BioTherapeutics gives investors a sense of the degree to which investors are betting on the decline of Aeglea BioTherapeutics's stock. Short interest data is updated every two weeks.

Short Interest

121.2K

Short Interest %

3.03%

Days to Cover

1.89
Data brought to you by Benzinga APIs

Looking for the most shorted stocks?

Aeglea BioTherapeutics Stock (NASDAQ:AGLE), Short Interest Report

Short interest for Aeglea BioTherapeutics gives investors a sense of the degree to which investors are betting on the decline of Aeglea BioTherapeutics's stock. Short interest data is updated every two weeks.

Short Interest

121.2K

Short Interest %

3.03%

Days to Cover

1.89
Data brought to you by Benzinga APIs

Looking for the most shorted stocks?

Aeglea BioTherapeutics Stock (NASDAQ:AGLE), Short Interest Report

Short interest for Aeglea BioTherapeutics gives investors a sense of the degree to which investors are betting on the decline of Aeglea BioTherapeutics's stock. Short interest data is updated every two weeks.

Short Interest

121.2K

Short Interest %

3.03%

Days to Cover

1.89
Data brought to you by Benzinga APIs

Looking for the most shorted stocks?

Aeglea BioTherapeutics Stock (NASDAQ:AGLE), Short Interest Report

Short interest for Aeglea BioTherapeutics gives investors a sense of the degree to which investors are betting on the decline of Aeglea BioTherapeutics's stock. Short interest data is updated every two weeks.

Short Interest

121.2K

Short Interest %

3.03%

Days to Cover

1.89
Data brought to you by Benzinga APIs

Looking for the most shorted stocks?

Aeglea BioTherapeutics Stock (NASDAQ:AGLE), Short Interest Report

Short interest for Aeglea BioTherapeutics gives investors a sense of the degree to which investors are betting on the decline of Aeglea BioTherapeutics's stock. Short interest data is updated every two weeks.

Short Interest

121.2K

Short Interest %

3.03%

Days to Cover

1.89
Data brought to you by Benzinga APIs

Looking for the most shorted stocks?

Aeglea BioTherapeutics Stock (NASDAQ:AGLE), Short Interest Report

Short interest for Aeglea BioTherapeutics gives investors a sense of the degree to which investors are betting on the decline of Aeglea BioTherapeutics's stock. Short interest data is updated every two weeks.

Short Interest

121.2K

Short Interest %

3.03%

Days to Cover

1.89
Data brought to you by Benzinga APIs

Looking for the most shorted stocks?

Aeglea BioTherapeutics Stock (NASDAQ:AGLE), Short Interest Report

Short interest for Aeglea BioTherapeutics gives investors a sense of the degree to which investors are betting on the decline of Aeglea BioTherapeutics's stock. Short interest data is updated every two weeks.

Short Interest

121.2K

Short Interest %

3.03%

Days to Cover

1.89
Data brought to you by Benzinga APIs

Looking for the most shorted stocks?

Aeglea BioTherapeutics Stock (NASDAQ:AGLE), Short Interest Report

Short interest for Aeglea BioTherapeutics gives investors a sense of the degree to which investors are betting on the decline of Aeglea BioTherapeutics's stock. Short interest data is updated every two weeks.

Short Interest

121.2K

Short Interest %

3.03%

Days to Cover

1.89
Data brought to you by Benzinga APIs

Looking for the most shorted stocks?

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga

© 2023 Benzinga | All Rights Reserved